Humira, the drug that built AbbVie (NYSE:ABBV), sold $756 million last quarter, down 35.9%. And yet total revenue still ...
The approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of the company’s two ...
Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...
Yusimry is indicated to treat a range of inflammatory and autoimmune conditions, including rheumatoid arthritis, Crohn’s ...
Amgen’s Humira biosimilar was the first to cross the FDA finish line back in 2016. (iStock / Getty Images Plus / z_wei) No more waiting: Humira’s judgment day has finally arrived. The first Humira ...
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...
CVS Health is the first major player to end some of its Humira coverage in order to make way for biosimilars. (CVS) This year, CVS Health plans to employ the classic "out with the old, in with the new ...
The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...
Pharmaceutical giant AbbVie (ABBV +0.73%) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current share price. This week Humira, which treats ...
Humira (adalimumab) and Remicade (infliximab) are prescription drugs used to treat certain inflammatory conditions. Humira is given as an injection, while Remicade is given as an infusion. Humira and ...
5d
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results